GEN highlights six AI-based drug discoverers worthy of note based on pipeline or platform progress, and in one instance, a ...

Alector has significant cash reserves but faces high cash burn, with no immediate catalysts and uncertain prospects for its ...

The stock is on the nasdaq top gainers list today on Acquisition news, currently trading at 9.3, up 6.49, gaining 226.92% on volume of over 28 Million shares as of this report.

Cassava Sciences stock plummeted Monday after the company's Alzheimer's treatment failed in Phase 3 testing. Roche's Proposed ...

Dundee University spin-out Exscientia has been taken over by US pharmaceutical rival Recursion, in a deal worth around £500m. The firm was delisted from the NASDAQ stock exchange on Wednesday after ...

CAMP4 Therapeutics Corporation (“CAMP4”) (Nasdaq: CAMP), a clinical-stage biotechnology company developing a pipeline of regRNA-targeting therapeutics designed to upregulate gene expression with the ...

Novartis increases mid-term sales growth forecast to 6% CAGR for 2023-2028, citing robust growth drivers, upcoming launches, ...

Biodexa-ClinicalPrograms Biodexa?s clinical programs from left to right: MTX110 for rGBM brain cancer, Tolimidone for Type 1 ...

ROUYN-NORANDA, Quebec, Nov. 21, 2024 (GLOBE NEWSWIRE) -- GLOBEX MINING ENTERPRISES INC. (GMX - Toronto Stock Exchange, G1MN - ...

Recursion unveils post-combination technology-enabled portfolio with more than 10 clinical and preclinical programs, 10 ...

a preclinical-stage, novel bispecific antibody directed against both TSLP and IL4R, according to a release. Traders […] "Lorem ipsum dolor sit amet, consectetur adipiscing elit, sed do eiusmod tempor ...

Incyte led S&P 500 decliners Tuesday afternoon after the pharmaceutical firm said it will stop developing one drug and pause ...